Your session is about to expire
← Back to Search
Chemotherapy + Stem Cell Transplant for Solid Cancers
Study Summary
This trial is studying a combination of drugs as a possible treatment for patients with solid tumors.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have HIV.Adults need to have good lung function, and for children, a certain measure of lung function needs to be met.You need to wait at least 2 weeks after your last treatment before joining the study.You have certain types of cancer and have responded well to chemotherapy, surgery, or radiotherapy.Your kidneys work well enough, as shown by a test measuring how well they filter waste from your blood.Your heart is strong and pumps blood well, as shown by a certain test called echocardiogram or MUGA.Your liver is working well, as shown by specific blood test results for bilirubin, SGOT, and SGPT.Your blood test shows that your platelet count is higher than 50,000/ul and your granulocyte count is at least 750 ul.If you had treatment before, it should have tried to make your condition better. If you had surgery, chemotherapy, or radiation before, it should not have included your lungs. You should only be considered if your primary site shows a complete response or partial response to the treatment.Your diagnosis has been confirmed by a pathology department, and if the cancer has come back or spread, it needs to be confirmed again by a pathologist, except for certain brain tumors and neuroblastoma.You have confirmed cancer spread to the bone marrow within 30 days of starting the treatment. If the cancer has mostly cleared from the bone marrow, you may still be eligible.You have trouble with daily activities and tasks because of your health condition.Children with certain types of advanced solid tumors who have responded at least partially to initial treatments.
- Group 1: Arm I
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA authorized autologous hematopoietic stem cell transplantation?
"Assessing its safety on a 1 to 3 scale, autologous hematopoietic stem cell transplantation received a score of one due to the limited amount of data available for this Phase 1 trial."
Is this clinical research accepting new participants at the moment?
"At this time, recruitment for this clinical trial has ended. Initially posted on February 26th 2007 with the last update being March 17th 2022, individuals seeking to participate in trials related to ewing sarcoma or autologous hematopoietic stem cell transplantation may have better luck; there are presently 4358 and 365 active studies respectively recruiting patients."
Is this clinical research endeavor open to adults aged 18 and older?
"This clinical trial is enrolling participants aged between 6 months and 40 years."
What are the criteria for individuals to be selected for this research?
"This clinical study is recruiting 25 paediatric patients between 6 months and 40 years of age that have been diagnosed with ewing sarcoma. To be eligible, participants must meet the following criteria: Have attempted to achieve a complete or partial response; pre-transplant modalities may include surgery, chemotherapy, or radiation therapy (excluding lung fields); only patients in CR/PR at the primary site can participate; histological confirmation from an Anatomic Pathology Department for recurrent/metastatic disease; no contraindications to stem cell collection via apheresis or bone marrow harvesting; signed voluntary informed consent according to institutional & federal guidelines"
In what cases do doctors usually advise autologous hematopoietic stem cell transplantation?
"Autologous hematopoietic stem cell transplantation is a therapeutic option for acute myelocytic leukemia, allogeneic hematopoietic stem cell transplant, chronic myelogenous leukemia, sarcoma and essential thrombocythemia."
How many participants are currently undergoing the therapy being tested in this trial?
"At this time, the study in question is not accepting participants. This medical trial was initially posted on February 26th of 2007 and updated most recently on March 17th of 2022. If you are looking for alternative studies to join, there are currently 4358 ewing sarcoma-related trials open as well as 365 autologous hematopoietic stem cell transplantation experiments actively enrolling patients."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger